A5027175466- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Reproductive System and Pregnancy
- Immune Cell Function and Interaction
- Renal cell carcinoma treatment
- IL-33, ST2, and ILC Pathways
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Urologic and reproductive health conditions
- Urological Disorders and Treatments
- Multiple and Secondary Primary Cancers
- Immunotherapy and Immune Responses
- Testicular diseases and treatments
- Cancer Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Cancer Genomics and Diagnostics
- Lignin and Wood Chemistry
- Genetic factors in colorectal cancer
- Radiopharmaceutical Chemistry and Applications
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
Hôpital Saint-Louis
2017-2025
Université Paris Cité
2014-2025
Assistance Publique – Hôpitaux de Paris
2014-2025
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2018-2022
Unité de catalyse et de chimie du solide de Lille
2018-2021
Catalyse
2018-2021
Reading Hospital
2021
Trinity College Dublin
2021
Cliniques Universitaires Saint-Luc
2021
Institut Catholique d'Arts et Métiers
2021
Abstract Background Therapeutic control of HIV replication reduces the size viral reservoir, particularly among central memory CD4+ T cells, and this effect might be accentuated by early treatment. Methods We examined ART initiated at time primary infection (early ART), lasting 2 6 years in 11 10 patients, respectively, on reservoir peripheral resting sorted into naive (TN), (TCM), transitional (TTM) effector (TEM) comparison with post-treatment controllers (PTCs). Results Between baseline...
Abstract Only some cancer patients respond to the immune-checkpoint inhibitors being used in clinic, and other therapeutic targets are sought. Here, we investigated HLA-G/ILT2 checkpoint clear-cell renal-cell carcinoma (ccRCC) focused on tumor-infiltrating CD8+ T lymphocytes (TIL) expressing HLA-G receptor ILT2. Using transcriptomics flow cytometry, characterized both peripheral blood CD8+ILT2+ cells from as late-differentiated CD27–CD28–CD57+ cytotoxic effectors. We observed a clear...
Few prognostic factors have been identified in patients with metastatic urothelial carcinoma (mUC) treated immune checkpoint inhibitors (ICIs). The Lung Immune Prognostic Index (LIPI) was associated clinical outcomes for ICIs several tumor types. We aim to assess the value of LIPI mUC ICIs. A retrospective ICI cohort and a validation (SAUL cohort) included, respectively, 8 European centers (any line) atezolizumab second or further line. chemotherapy-only also analyzed. score based on 2...
722 Background: Upper tract urothelial carcinoma is a rare and heterogeneous disease that accounts for up to 5% of all neoplasms. Variant histology an important prognostic factor in patients affected by bladder cancer its presence associated with adverse pathological features worse survival outcomes. However, few data exists regarding the impact histological variants UTUC treated systemic therapy. Methods: PEMBROBLAD retrospective multicenter RW study conducted 24 French GETUG centers....
735 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) and radical cystectomy is the gold standard in localized muscle-invasive bladder cancer (MIBC), for fit patients. However, NAC less prescribed older patients, mainly due to safety concerns. This study aimed evaluate feasibility efficacy of patients aged ≥ 75. Methods: We retrospectively included from 14 French GETUG centers. All had received at least one cycle cisplatin-based MIBC, between 2010 2022. Primary outcome was evaluated...
Tumor spheroids play an increasingly important role in cancer research. Their ability to recapitulate crucial features of tumor biology that are lost the classically used 2D models along with their relative simplicity and handiness have made them most studied 3D model. application as a theranostic tool or means study tumor-host interaction is now well-established various cancers. However, use field Renal Cell Carcinoma (RCC) remains very limited. The aim this work present methods implement...
Urachal cancer (UrC) is a rare, non-urothelial malignancy. Its natural history and management are poorly understood. Although localized to the bladder dome, most common histological subtype of UrC adenocarcinoma. develops from an embryonic remnant, frequently diagnosed in advanced stage with poor prognosis. The treatment not standardized, based only on case reports small series. This large retrospective multicentric study was conducted by French Genito-Urinary Tumor Group gain better...
Collecting duct carcinoma (CDC) and renal medullary (RMC) are two rare subtypes of kidney cancer with a poor prognosis in the metastatic setting. Beyond first-line treatment, there no standard-of-care therapies. This retrospective study assessed efficacy treatments after chemotherapy 57 patients (m) CDC (n = 35) or RMC 22) treated between 2010 2019 at 11 French centers. The median age was 53 years; overall, 60% 34) were diagnosis. After follow-up 13 months, overall survival 12 (95% CI,...
Recurrence of non-muscle invasive bladder cancer (NMIBC) after initial management occurs in 60-70% patients. Predictive criteria for recurrence remain only clinical and pathological. The aim this study was to investigate the prognostic significance proportion checkpoint HLA-G's receptor ILT2-expressing peripheral CD8+ T cells.The CD4+ILT2+and CD8+ILT2+ cells not increased NMIBC compared controls. However, a strong association found between cell population levels (p = 0.0006). Two-year...
The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. safety systemic anti-cancer therapy in oncology patients with non-severe COVID-19 is an important matter daily practice.ONCOSARS-1 was a single-center, academic observational study. Adult solid tumors treated day unit during initial phase Belgium were prospectively included. All (n = 363)...
Introduction Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial (non-UC)] for which no treatment guidelines available. We aim to evaluate the efficacy systemic treatments in VH non-UC cancers. Materials Multicenter retrospective analysis patients treated advanced metastatic Primary endpoint was overall response rate (ORR) according line, regimen and histology subtype. Secondary endpoints were progression-free survival...
Mammalian target of rapamycin (mTOR) regulates cellular functions by integrating intracellular signals and from the tumor microenvironment (TME). The PI3K-AKT-mTOR pathway is activated in 70% head neck squamous cell carcinoma (HNSCC) associated with poor prognosis. This phase I-II study investigated effect mTOR inhibition using weekly everolimus (30 mg for dose level 1, 50 2) combined induction chemotherapy (AUC2 carboplatin 60 mg/m2 paclitaxel) treatment-naïve patients locally advanced...
Abstract A clean method has been developed for the α‐allylation of phenyl and alpha alkyl acetonitrile with allylic alcohols. The reaction is catalyzed by nickel complexes in situ generated from a combination Ni(cod) 2 dppf ligand performed at 80 °C methanol as solvent. Accordingly to this simple base‐free protocol that only yields water side‐product, many nitriles were synthetized good yields. magnified image
Background: The identification of activating mutations in specific genes led to the development targeted therapies for NSCLC. TKI directed against EGFR-mutations were first prove their major efficacy. Medical associations recommend use as and second-line metastatic treatments EGFR-mutated patients. Our objective was analyze survival patients treated beyond second line treatment. Methods: We performed a longitudinal, retrospective analytical study at APHP (Assistance Publique Hopitaux de...
545 Background: Prognostic factors for survival in metastatic urothelial carcinoma (mUC) have been reported patients (pts) treated with chemotherapy (Bellmunt and al, JCO 2010). However, no biomarkers clearly identified the setting of immune-checkpoint inhibitors (ICI). The Lung immune prognostic index (LIPI) was associated clinical outcomes ICI lung cancer (Mezquita et Jama Oncol 2018) other tumor types (Varga TAT 2019). In this multicenter retrospective study, we correlated LIPI pts mUC...